Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD20-targeted therapy: the next generation of antibodies.
van Meerten T, Hagenbeek A. van Meerten T, et al. Among authors: hagenbeek a. Semin Hematol. 2010 Apr;47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007. Semin Hematol. 2010. PMID: 20350667 Review.
HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC. van Meerten T, et al. Among authors: hagenbeek a. Haematologica. 2010 Dec;95(12):2063-71. doi: 10.3324/haematol.2010.025783. Epub 2010 Sep 17. Haematologica. 2010. PMID: 20851867 Free PMC article.
Novel antibodies against follicular non-Hodgkin's lymphoma.
van Meerten T, Hagenbeek A. van Meerten T, et al. Among authors: hagenbeek a. Best Pract Res Clin Haematol. 2011 Jun;24(2):231-56. doi: 10.1016/j.beha.2011.03.002. Epub 2011 May 5. Best Pract Res Clin Haematol. 2011. PMID: 21658621 Review.
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, Losic N, Radford J. Hagenbeek A, et al. Blood. 2008 Jun 15;111(12):5486-95. doi: 10.1182/blood-2007-10-117671. Epub 2008 Apr 4. Blood. 2008. PMID: 18390837 Free article. Clinical Trial.
Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M. Hagenbeek A, et al. Anticancer Drugs. 2002 Nov;13 Suppl 2:S11-7. Anticancer Drugs. 2002. PMID: 12710586 Review.
B-cell involvement in chronic graft-versus-host disease.
Kapur R, Ebeling S, Hagenbeek A. Kapur R, et al. Among authors: hagenbeek a. Haematologica. 2008 Nov;93(11):1702-11. doi: 10.3324/haematol.13311. Epub 2008 Aug 25. Haematologica. 2008. PMID: 18728020 Free article.
Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
Van Oers MH, Hagenbeek A, Van Glabbeke M, Teodorovic I. Van Oers MH, et al. Among authors: hagenbeek a. Ann Hematol. 2002 Oct;81(10):553-7. doi: 10.1007/s00277-002-0548-2. Epub 2002 Oct 17. Ann Hematol. 2002. PMID: 12424535 Clinical Trial. No abstract available.
252 results